GlassScriptPhysician profile
Narendra S Punjabi
NPI 1295740751
$1,523.86
in general payments reported to CMS, 2019-2025
24 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $311 · 2021: $167 · 2022: $73.26 · 2023: $337 · 2024: $299 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $745.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $224.45 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $167.33 | 2024 | Airsupra, Breztri |
| Indivior INC. | $157.51 | 2020-2023 | Sublocade |
| Arbor Pharmaceuticals, INC. | $147.98 | 2019-2021 | |
| Allergan, INC. | $124.50 | 2019-2020 | |
| Antares Pharma, INC. | $85.11 | 2023-2024 | Xyosted, Tlando, Nocdurna |
| Acella Pharmaceuticals, LLC | $75.18 | 2019-2025 | NP Thyroid 60 |
| Neos Therapeutics, LP | $69.01 | 2019-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $58.60 | 2024 | |
| Redhill Biopharma INC. | $57.82 | 2022-2023 | Talicia |
| Orexo US, INC. | $50.77 | 2019 | |
| Halozyme INC | $49.19 | 2023 | |
| Boston Scientific Corporation | $33.36 | 2020 | |
| Abbott Laboratories | $31.44 | 2022-2023 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $25.70 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $24.90 | 2025 | |
| Ironshore Pharmaceuticals INC. | $22.42 | 2024 | |
| Exact Sciences Corporation | $21.72 | 2025 | The Cologuard Plus Collection Kit |
| Xeris Pharmaceuticals, INC. | $21.35 | 2021 | |
| Acerus Pharmaceuticals Corporation | $17.36 | 2021 | |
| Tolmar, INC. | $16.16 | 2025 | Jatenzo |
| Greer Laboratories, INC. | $15.81 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.31 | 2020 | |
| Idorsia Pharmaceuticals US INC | $12.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narendra Punjabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.